← 返回

原发性颅神经淋巴瘤病的临床与基因组特征

英文原题:Clinical and Genomic Profile of Primary Cranial Neurolymphomatosis.

查看英文原题

Clinical and Genomic Profile of Primary Cranial Neurolymphomatosis.

PubMed 2024/06/24(内容时间) J Blood Med Q3 · IF 2.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

原发性颅神经淋巴瘤病是一种罕见的原发性中枢神经系统淋巴瘤亚型,病变局限于颅神经。本报告描述一例成功进行基因组分析的病例。57岁男性在确诊前约30个月出现多次颅神经病变并接受激素治疗。确诊时右侧第V、VI和VII对颅神经受累;海绵窦病灶活检显示大B细胞淋巴瘤浸润神经纤维。疾病侵袭性强且难治,尽管接受化学免疫治疗、布鲁顿酪氨酸激酶抑制剂、放疗、自体移植、CAR-T 及全脑放疗,仍进展至颈髓神经、脑脊液、室管膜和脑实质。患者自确诊存活22个月,自首次颅神经症状起存活52个月。测序发现常见于原发中枢神经系统淋巴瘤的MYD88、CD79B和PIM1突变;另有22个PIM1突变,提示异常体细胞高频突变活跃,以及两种此前未在该病中描述的CXCR4错义突变,可能具有生物学和治疗意义。

展开英文摘要原文

Primary cranial neurolymphomatosis (PCNL) is a rare subtype of primary CNS lymphoma (PCNSL) in which infiltrative lymphomatous involvement is confined to cranial nerves.

Here, we report a case of PCNL with successful genomic profiling. A 57-year-old male had a lengthy prediagnostic phase spanning approximately 30 months, characterized by multiple episodes of cranial neuropathies managed by steroids. At the time of diagnosis, the patient had right-sided cranial neuropathies involving cranial nerves (CN) V, VI, and VII. Pathological findings of the right cavernous lesion biopsy were consistent with large B-cell lymphoma-infiltrating nerve fibers. The clinical course was aggressive and refractory, characterized by relentless progression with the development of cervical spinal neurolymphomatosis, cerebrospinal fluid involvement, and ependymal and intraparenchymal cerebral involvement, despite multiple lines of therapy, including chemoimmunotherapy, Bruton's tyrosine kinase inhibitor, radiation, autologous stem cell transplant, chimeric antigen receptor T-cell therapy (CAR-T), and whole-brain radiation.

The patient survived for 22 months from the time of the initial diagnosis and 52 months after the first episode of cranial neuropathy. Next-generation sequencing identified mutations (MYD88, CD79b, and PIM1) that are frequently observed in PCNSL. The unusual findings included a total of 22 mutations involving PIM1, indicating a highly active aberrant somatic hypermutation and two missense CXCR4 mutations. CXCR4 mutations have never been described in PCNSL and may have implications for disease biology and therapeutic interventions.

We provide a literature review to further elucidate PCNL.

论文信息

作者
Wolf EB、Imperial R、Jiang L、Agarwal AK、Tun HW
单位
Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.United States
文献类型
病例报告
期刊
Journal of blood medicine2024
原文标识
PubMed 38947230 · DOI 10.2147/JBM.S459123